Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm (Q38115132)

29 August 2017

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm (English)

1 reference

29 August 2017

Iain B McInnes

3

0 references

Naveed Sattar

series ordinal

4

object named as

Naveed Sattar

1 reference

29 August 2017

Jamie Robertson

1

1 reference

29 August 2017

Mike J Peters

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

18 June 2013

1 reference

Nature Reviews Rheumatology

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

513-523

1 reference

29 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.91

29 August 2017

0 references

cites work

Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Major lipids, apolipoproteins, and risk of vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Total cholesterol and LDL levels decrease before rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Changes in the concentration and composition of plasma lipoproteins during the acute phase response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.91

Lipid profiles in untreated patients with rheumatoid arthritis

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23774906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23774906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Atherogenic lipid profiles in rheumatoid arthritis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23774906

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2013.91

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference